glp 1 gip triple agonist Discovery of a potent and long-acting Xenopus GLP-1-based GLP-1/glucagon/Y2 receptor Upcoming wave of hormone-based therapies
Description
Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis
Mechanistically, L-tryptophan upregulated the expression of GLP-1related genes (e.g., Gcg and Pcsk1 ) in intestinal L cells, further promoting GLP-1 production ( In contrast, some postbiotics may suppress GLP-1 signaling
In fact, a double-masked, placebo-controlled study found that Byetta (exenatide, AstraZeneca), a GLP-1 receptor agonist for diabetes, lowered intracranial pressure (ICP) by 5.7 cm H 2 O within 2.5 hours in women with active IIH ( P = .048), a benefit that was sustained across 12 weeks
In the ELIXA trial, Pfeffer et al 27 evaluated the effect of lixisenatide in patients with type 2 diabetes with myocardial infarction or unstable angina admission in the previous 180 days
doi:10.1016/j.bbrc.2017.06.031 41
Mutual Antagonism of Wilms Tumor 1 and -Catenin Dictates Podocyte Health and Disease
